Poseida Therapeutics (PSTX) Prices 20M Share Offering at $3.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- S&P 500, Nasdaq futures slip after tech rally; Warsh's speech awaited
- Oil holds steady, on track for weekly fall on US-Iran talks stalemate
- Dollar heads for weekly gain as Warsh remarks awaited
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
August 4, 2022 8:00 AM EDTSAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.50 per share. The gross proceeds to Poseida from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $70.0... More
